Overview

CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

Status:
Active, not recruiting

Trial end date:
2021-11-02

Target enrollment:

Participant gender:

Summary

The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: CD24Fc vs placebo with the standard GVHD prophylaxis of tacrolimus / methotrexate.

Phase:

Phase 3

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.
OncoImmune, Inc.

Treatments:

Methotrexate
Tacrolimus